• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

一级决定 p53 聚集机制及其意义。

First-order rate-determining aggregation mechanism of p53 and its implications.

机构信息

MRC Laboratory of Molecular Biology, Cambridge, United Kingdom.

出版信息

Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13590-5. doi: 10.1073/pnas.1211557109. Epub 2012 Aug 6.

DOI:10.1073/pnas.1211557109
PMID:22869710
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3427100/
Abstract

Aggregation of p53 is initiated by first-order processes that generate an aggregation-prone state with parallel pathways of major or partial unfolding. Here, we elaborate the mechanism and explore its consequences, beginning with the core domain and extending to the full-length p53 mutant Y220C. Production of large light-scattering particles was slower than formation of the Thioflavin T-binding state and simultaneous depletion of monomer. EDTA removes Zn(2+) to generate apo-p53, which aggregated faster than holo-p53. Apo-Y220C also aggregated by both partial and major unfolding. Apo-p53 was not an obligatory intermediate in the aggregation of holo-p53, but affords a parallel pathway that may be relevant to oncogenic mutants with impaired Zn(2+) binding. Full-length tetrameric Y220C formed the Thioflavin T-binding state with similar rate constants to those of core domain, consistent with a unimolecular initiation that is unaffected by neighboring subunits, but very slowly formed small light-scattering particles. Apo-Y220C and aggregated holo-Y220C had little, if any, seeding effect on the initial polymerization of holo-Y220C (measured by Thioflavin T binding), consistent with initiation being a unimolecular process. But apo-Y220C and aggregated holo-Y220C accelerated somewhat the subsequent formation of light-scattering particles from holo-protein, implying coaggregation. The implications for cancer cells containing wild-type and unstable mutant alleles are that aggregation of wild-type p53 (or homologs) might not be seeded by aggregated mutant, but it could coaggregate with p53 or other cellular proteins that have undergone the first steps of aggregation and speed up the formation of microscopically observable aggregates.

摘要

p53 的聚集首先由一级过程引发,这些过程产生具有平行展开主要或部分途径的聚集倾向状态。在这里,我们详细阐述了这种机制,并探讨了其后果,从核心结构域开始,扩展到全长 p53 突变体 Y220C。大的光散射颗粒的产生速度比硫代黄素 T 结合状态的形成和单体的同时耗散慢。EDTA 去除 Zn(2+)以生成 apo-p53,其聚集速度比 holo-p53 快。apo-Y220C 也通过部分和主要展开进行聚集。apo-p53 不是 holo-p53 聚集的必需中间产物,但提供了一个平行途径,可能与 Zn(2+)结合受损的致癌突变体有关。全长四聚体 Y220C 以与核心结构域相似的速率常数形成硫代黄素 T 结合状态,这与不受相邻亚基影响的单分子引发一致,但非常缓慢地形成小的光散射颗粒。apo-Y220C 和聚集的 holo-Y220C 对 holo-Y220C 的初始聚合(通过硫代黄素 T 结合测量)几乎没有,如果有的话,种子效应,这与引发是一个单分子过程一致。但是 apo-Y220C 和聚集的 holo-Y220C 稍微加速了来自 holo-蛋白的光散射颗粒的随后形成,这意味着共聚集。对于含有野生型和不稳定突变体等位基因的癌细胞的影响是,野生型 p53(或同源物)的聚集可能不会被聚集的突变体引发,但它可能与已经经历聚集的第一步的 p53 或其他细胞蛋白共聚集,并加速显微镜可见聚集的形成。

相似文献

1
First-order rate-determining aggregation mechanism of p53 and its implications.一级决定 p53 聚集机制及其意义。
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13590-5. doi: 10.1073/pnas.1211557109. Epub 2012 Aug 6.
2
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.p53 致癌突变体聚集的动力学机制及其抑制。
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13584-9. doi: 10.1073/pnas.1211550109. Epub 2012 Aug 6.
3
Propagation of aggregated p53: Cross-reaction and coaggregation vs. seeding.聚集型p53的传播:交叉反应与共聚集对比种子效应
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2443-8. doi: 10.1073/pnas.1500262112. Epub 2015 Feb 9.
4
Multifunctional Compounds for Activation of the p53-Y220C Mutant in Cancer.多功能化合物激活癌症中的 p53-Y220C 突变体。
Chemistry. 2018 Dec 3;24(67):17734-17742. doi: 10.1002/chem.201802677. Epub 2018 Nov 9.
5
Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.突变型 p53 聚集形成朊病毒样淀粉样寡聚体和纤维:对癌症的影响。
J Biol Chem. 2012 Aug 10;287(33):28152-62. doi: 10.1074/jbc.M112.340638. Epub 2012 Jun 19.
6
Kinetic instability of p53 core domain mutants: implications for rescue by small molecules.p53核心结构域突变体的动力学不稳定性:小分子拯救的意义
J Biol Chem. 2003 Jun 27;278(26):24108-12. doi: 10.1074/jbc.M302458200. Epub 2003 Apr 16.
7
Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.苯并噻唑衍生物稳定热不稳定的 p53 癌突变体 Y220C,并在 p53-Y220C 细胞系中显示抗癌活性。
Eur J Med Chem. 2018 May 25;152:101-114. doi: 10.1016/j.ejmech.2018.04.035. Epub 2018 Apr 21.
8
Wild type p53 function in p53 mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence.用从 Ashwagandha 中提取的具有抗癌作用的 withanolides 处理携带 p53 突变的细胞,恢复野生型 p53 功能:生物信息学和实验证据。
J Exp Clin Cancer Res. 2019 Feb 26;38(1):103. doi: 10.1186/s13046-019-1099-x.
9
Anticancer therapeutic strategies for targeting mutant p53-Y220C.靶向突变型p53-Y220C的抗癌治疗策略。
J Biomed Res. 2024 May 13;38(3):222-232. doi: 10.7555/JBR.37.20230093.
10
An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein.一种用于识别蛋白质中稳定口袋的计算机模拟算法:测试案例,p53肿瘤抑制蛋白的Y220C突变体
Protein Eng Des Sel. 2016 Sep;29(9):377-90. doi: 10.1093/protein/gzw035. Epub 2016 Aug 8.

引用本文的文献

1
Molecular targets and therapies associated with poor prognosis of triple‑negative breast cancer (Review).与三阴性乳腺癌预后不良相关的分子靶点与治疗(综述)
Int J Oncol. 2025 Jun;66(6). doi: 10.3892/ijo.2025.5758. Epub 2025 May 30.
2
Unveiling the multifaceted potential of amyloid fibrils: from pathogenic myths to biotechnological marvels.揭示淀粉样纤维的多面潜力:从致病谜团到生物技术奇迹。
Biophys Rev. 2024 Sep 30;16(6):737-751. doi: 10.1007/s12551-024-01232-3. eCollection 2024 Dec.
3
Covalent Fragments Acting as Tyrosine Mimics for Mutant p53-Y220C Rescue by Nucleophilic Aromatic Substitution.通过亲核芳香取代作用作为酪氨酸模拟物用于突变型p53-Y220C拯救的共价片段
ACS Pharmacol Transl Sci. 2024 Nov 18;7(12):3984-3999. doi: 10.1021/acsptsci.4c00414. eCollection 2024 Dec 13.
4
Kinetic models reveal the interplay of protein production and aggregation.动力学模型揭示了蛋白质产生与聚集之间的相互作用。
Chem Sci. 2024 May 10;15(22):8430-8442. doi: 10.1039/d4sc00088a. eCollection 2024 Jun 5.
5
Anticancer therapeutic strategies for targeting mutant p53-Y220C.靶向突变型p53-Y220C的抗癌治疗策略。
J Biomed Res. 2024 May 13;38(3):222-232. doi: 10.7555/JBR.37.20230093.
6
Reconnaissance of Allostery via the Restoration of Native p53 DNA-Binding Domain Dynamics in Y220C Mutant p53 Tumor Suppressor Protein.通过恢复Y220C突变型p53肿瘤抑制蛋白中天然p53 DNA结合结构域动力学来探测变构作用
ACS Omega. 2024 Apr 22;9(18):19837-19847. doi: 10.1021/acsomega.3c08509. eCollection 2024 May 7.
7
Understanding the prion-like behavior of mutant p53 proteins in triple-negative breast cancer pathogenesis: The current therapeutic strategies and future directions.了解三阴性乳腺癌发病机制中突变型p53蛋白的朊病毒样行为:当前的治疗策略和未来方向。
Heliyon. 2024 Feb 10;10(4):e26260. doi: 10.1016/j.heliyon.2024.e26260. eCollection 2024 Feb 29.
8
p53 amyloid pathology is correlated with higher cancer grade irrespective of the mutant or wild-type form.p53 淀粉样蛋白病理学与更高的癌症分级相关,而与突变型或野生型形式无关。
J Cell Sci. 2023 Sep 1;136(17). doi: 10.1242/jcs.261017. Epub 2023 Sep 8.
9
Targeting p53 pathways: mechanisms, structures, and advances in therapy.靶向 p53 通路:机制、结构和治疗进展。
Signal Transduct Target Ther. 2023 Mar 1;8(1):92. doi: 10.1038/s41392-023-01347-1.
10
Anticancer Therapeutic Strategies Targeting p53 Aggregation.靶向 p53 聚集的抗癌治疗策略。
Int J Mol Sci. 2022 Sep 20;23(19):11023. doi: 10.3390/ijms231911023.

本文引用的文献

1
Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition.p53 致癌突变体聚集的动力学机制及其抑制。
Proc Natl Acad Sci U S A. 2012 Aug 21;109(34):13584-9. doi: 10.1073/pnas.1211550109. Epub 2012 Aug 6.
2
Allele-specific p53 mutant reactivation.等位基因特异性 p53 突变体的重新激活。
Cancer Cell. 2012 May 15;21(5):614-625. doi: 10.1016/j.ccr.2012.03.042.
3
Halogen-enriched fragment libraries as leads for drug rescue of mutant p53.富含卤素的片段文库作为拯救突变型 p53 药物的先导物。
J Am Chem Soc. 2012 Apr 18;134(15):6810-8. doi: 10.1021/ja301056a. Epub 2012 Apr 5.
4
The amyloid state of proteins in human diseases.蛋白质在人类疾病中的淀粉样状态。
Cell. 2012 Mar 16;148(6):1188-203. doi: 10.1016/j.cell.2012.02.022.
5
Electrocatalytic monitoring of metal binding and mutation-induced conformational changes in p53 at picomole level.皮摩尔级检测金属结合和突变诱导的 p53 构象变化的电催化监测。
J Am Chem Soc. 2011 May 11;133(18):7190-6. doi: 10.1021/ja201006s. Epub 2011 Apr 14.
6
Interaction of the p53 DNA-binding domain with its n-terminal extension modulates the stability of the p53 tetramer.p53 DNA 结合域与其 N 端延伸的相互作用调节 p53 四聚体的稳定性。
J Mol Biol. 2011 Jun 10;409(3):358-68. doi: 10.1016/j.jmb.2011.03.047. Epub 2011 Mar 30.
7
Gain of function of mutant p53 by coaggregation with multiple tumor suppressors.突变型 p53 与多个肿瘤抑制因子共聚集获得功能。
Nat Chem Biol. 2011 May;7(5):285-95. doi: 10.1038/nchembio.546. Epub 2011 Mar 27.
8
Single-Molecule characterization of oligomerization kinetics and equilibria of the tumor suppressor p53.单分子技术解析肿瘤抑制因子 p53 寡聚化动力学和平衡。
Nucleic Acids Res. 2011 Mar;39(6):2294-303. doi: 10.1093/nar/gkq800. Epub 2010 Nov 18.
9
Folding of tetrameric p53: oligomerization and tumorigenic mutations induce misfolding and loss of function.四聚体 p53 的折叠:寡聚化和致瘤突变诱导错误折叠和功能丧失。
J Mol Biol. 2010 Jan 29;395(4):705-16. doi: 10.1016/j.jmb.2009.11.013. Epub 2009 Nov 11.
10
Lumry-Eyring nucleated-polymerization model of protein aggregation kinetics. 2. Competing growth via condensation and chain polymerization.蛋白质聚集动力学的Lumry-Eyring成核聚合模型。2. 通过缩合和链式聚合的竞争生长。
J Phys Chem B. 2009 May 14;113(19):7020-32. doi: 10.1021/jp8083088.